Anita Devlin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Anita Devlin has a total of 217 co-authors. Here are the top co-authors by number of shared publications:
Alessio Masi
Department of Neuroscience, Psychology, Drug Research and Child Health (NEUROFARBA), Section of Pharmacology and Toxicology, University of Florence, Florence, Italy
2 shared publicationsAnnalaura Torella
Department of Precision Medicine, University "Luigi Vanvitelli," Naples, Italy; Telethon Institute of Genetics and Medicine (TIGEM), Pozzuoli, Italy
2 shared publicationsAnnalisa Vetro
Neuroscience Department, Meyer Children's Hospital IRCCS, Florence, Italy
2 shared publicationsAtsushi Sugie
Brain Research Institute, Niigata University, Niigata 951-8585, Japan
2 shared publicationsCelina von Stülpnagel
Department of Pediatric Neurology and Developmental Medicine, Dr. v. Hauner Children's Hospital, LMU - University of Munich, München, Germany; Institute for Transition, Rehabilitation and Palliation, Paracelsus Medical University, Salzburg, Austria
2 shared publicationsCristiana Pelorosso
Neuroscience Department, Meyer Children's Hospital IRCCS, Florence, Italy
2 shared publications
Latest Publications
- 11 November 2025
- Published by BMJ in Archives of Disease in Childhood
- Vol. 111 (3) , 253-259
Transdermal clonidine patch use in the management of childhood hypertonia: a cross-sectional UK-wide service evaluation
Objectives Clonidine is increasingly used in the management of childhood motor disorders. Reports are limited regarding the use of transdermal clonidine patches (TCPs) for this indication. We aimed to explore the use of TCPs in children and young people (CAYP) across specialist movement disorder services in the UK. Methods A cross-sectional service evaluation of TCP use in CAYP with motor disorders was performed. Where available, historical data on TCP use were also collected. Results Data were available for 259 CAYP from 11 services, with 176/259 (68%) under active follow-up. Median age at starting TCPs was 8.6 years (25th to 75th centile 5.2–12 years). Gross Motor Function Classification System level (or equivalent) was V for 206/253 (81.4%) CAYP. Clinically significant chorea was observed in 33/255 (12.9%), spasticity in 116/254 (45.7%) and dystonia in 234/256 (91.4%) CAYP. The most common reasons for TCP initiation were overall dystonia severity (61/259, 23.6%), concerns about absorption of enteral medication (54/259, 20.8%) and excess sedation with enteral clonidine (46/259, 17.8%). TCP use had been discontinued by 61/259 (23.6%) CAYP, most commonly because of skin rash (24/259, 9.3%). The median time to discontinuing patches was 3.5 months. In addition to TCPs, 148/259 (57.1%) of CAYP continued with enteral clonidine. Additional tone-reducing medication use ranged from 0 to 6 additional medications (modal number of medications 3), Conclusion We present the first UK-based multicentre evaluation of TCP use in CAYP with motor disorders, highlighting the complexity of the medical problems of these CAYP and their clinical management. TCPs appear generally to be tolerated by CAYP, but further work is required to establish their efficacy.
- 11 November 2025
- Published by BMJ in Archives of Disease in Childhood
- Vol. 111 (3) , 253-259
Transdermal clonidine patch use in the management of childhood hypertonia: a cross-sectional UK-wide service evaluation
Objectives Clonidine is increasingly used in the management of childhood motor disorders. Reports are limited regarding the use of transdermal clonidine patches (TCPs) for this indication. We aimed to explore the use of TCPs in children and young people (CAYP) across specialist movement disorder services in the UK. Methods A cross-sectional service evaluation of TCP use in CAYP with motor disorders was performed. Where available, historical data on TCP use were also collected. Results Data were available for 259 CAYP from 11 services, with 176/259 (68%) under active follow-up. Median age at starting TCPs was 8.6 years (25th to 75th centile 5.2–12 years). Gross Motor Function Classification System level (or equivalent) was V for 206/253 (81.4%) CAYP. Clinically significant chorea was observed in 33/255 (12.9%), spasticity in 116/254 (45.7%) and dystonia in 234/256 (91.4%) CAYP. The most common reasons for TCP initiation were overall dystonia severity (61/259, 23.6%), concerns about absorption of enteral medication (54/259, 20.8%) and excess sedation with enteral clonidine (46/259, 17.8%). TCP use had been discontinued by 61/259 (23.6%) CAYP, most commonly because of skin rash (24/259, 9.3%). The median time to discontinuing patches was 3.5 months. In addition to TCPs, 148/259 (57.1%) of CAYP continued with enteral clonidine. Additional tone-reducing medication use ranged from 0 to 6 additional medications (modal number of medications 3), Conclusion We present the first UK-based multicentre evaluation of TCP use in CAYP with motor disorders, highlighting the complexity of the medical problems of these CAYP and their clinical management. TCPs appear generally to be tolerated by CAYP, but further work is required to establish their efficacy.
- Open Access
- 29 May 2025
- Published by Wiley in Epilepsia Open
- Vol. 10 (4) , 1120-1132
Ketogenic diet therapy for epilepsy during pregnancy and lactation: An international survey exploring clinician perspectives
Objective: Ketogenic diet therapies (KDTs) are increasingly used as a treatment for people with epilepsy of childbearing potential (PWECP) and glucose transporter type 1 deficiency syndrome (Glut1DS). The aim of this study was to collect information on clinical experience with KDT during pregnancy and lactation in these populations. Methods: Between December 2023 and June 2024, an online survey was widely circulated to healthcare professionals (HCPs) working with PWECP and people with Glut1DS of childbearing potential on KDT. The survey explored KDT use during pregnancy and lactation. Only HCPs working with patients who expressed interest in KDT and who were planning to become pregnant or were already pregnant were invited to complete the survey. Results: Thirty‐five HCPs had counseled patients about whether to follow KDT during pregnancy. Sixty percent of HCPs did not recommend KDT during pregnancy. Key concerns included a lack of expertise with KDT use during pregnancy, insufficient data on the safety of KDT use during pregnancy, and uncertainty about the impact on fetal development. Among the HCPs (40%) who recommended KDT during pregnancy, there was no consensus regarding the version of KDT or optimal macronutrient composition. Even fewer HCPs ( n = 5) had provided counseling on diet adaptation during lactation. Low Glycemic Index Treatment and the modified Atkins diet were most recommended. Blood ketone monitoring was unanimously recommended during lactation. Significance: Based on the survey results, HCPs have variable opinions about the safety, management, ideal diet, and levels of ketosis for people with epilepsy (PWE) and Glut1DS on KDT during pregnancy and lactation. There was consensus about monitoring ketosis levels and ensuring micronutrient supplementation. Patient enrollment in pregnancy registries that capture KDT use is crucial to support future research and expand knowledge about the safety of KDT so HCPs and PWE or Glut1DS can make informed decisions about their treatment. Plain Language Summary: Most healthcare providers (HCPs) did not advise ketogenic diet therapy (KDT) for epilepsy during pregnancy, though some noted exceptions for glucose transporter type 1 deficiency syndrome. Their main concerns were not having enough information about safety for the parent and fetus and their own lack of experience using KDT during pregnancy. The 40% of HCPs who supported the use of KDT during pregnancy stressed the need for personalized care and close monitoring to reduce risks. Few HCPs have used KDT during lactation. Experts advised using more flexible versions of KDT during lactation. More research is needed.
- 29 May 2025
- Published by Wiley in Epilepsia Open
- Vol. 10 (4) , 1120-1132
Open AccessKetogenic diet therapy for epilepsy during pregnancy and lactation: An international survey exploring clinician perspectives
Objective: Ketogenic diet therapies (KDTs) are increasingly used as a treatment for people with epilepsy of childbearing potential (PWECP) and glucose transporter type 1 deficiency syndrome (Glut1DS). The aim of this study was to collect information on clinical experience with KDT during pregnancy and lactation in these populations. Methods: Between December 2023 and June 2024, an online survey was widely circulated to healthcare professionals (HCPs) working with PWECP and people with Glut1DS of childbearing potential on KDT. The survey explored KDT use during pregnancy and lactation. Only HCPs working with patients who expressed interest in KDT and who were planning to become pregnant or were already pregnant were invited to complete the survey. Results: Thirty‐five HCPs had counseled patients about whether to follow KDT during pregnancy. Sixty percent of HCPs did not recommend KDT during pregnancy. Key concerns included a lack of expertise with KDT use during pregnancy, insufficient data on the safety of KDT use during pregnancy, and uncertainty about the impact on fetal development. Among the HCPs (40%) who recommended KDT during pregnancy, there was no consensus regarding the version of KDT or optimal macronutrient composition. Even fewer HCPs ( n = 5) had provided counseling on diet adaptation during lactation. Low Glycemic Index Treatment and the modified Atkins diet were most recommended. Blood ketone monitoring was unanimously recommended during lactation. Significance: Based on the survey results, HCPs have variable opinions about the safety, management, ideal diet, and levels of ketosis for people with epilepsy (PWE) and Glut1DS on KDT during pregnancy and lactation. There was consensus about monitoring ketosis levels and ensuring micronutrient supplementation. Patient enrollment in pregnancy registries that capture KDT use is crucial to support future research and expand knowledge about the safety of KDT so HCPs and PWE or Glut1DS can make informed decisions about their treatment. Plain Language Summary: Most healthcare providers (HCPs) did not advise ketogenic diet therapy (KDT) for epilepsy during pregnancy, though some noted exceptions for glucose transporter type 1 deficiency syndrome. Their main concerns were not having enough information about safety for the parent and fetus and their own lack of experience using KDT during pregnancy. The 40% of HCPs who supported the use of KDT during pregnancy stressed the need for personalized care and close monitoring to reduce risks. Few HCPs have used KDT during lactation. Experts advised using more flexible versions of KDT during lactation. More research is needed.
- Open Access
- 28 May 2025
- Published by Elsevier in Epilepsy & Behavior
- Vol. 171, 110481
An international survey on withdrawing the ketogenic diet therapy for epilepsy
- 28 May 2025
- Published by Elsevier in Epilepsy & Behavior
- Vol. 171, 110481
Open AccessAn international survey on withdrawing the ketogenic diet therapy for epilepsy
- Open Access
- 30 October 2024
- Published by Elsevier in European Journal of Paediatric Neurology
- Vol. 53, 131-137
Ketogenic diet registry for epilepsy: A cross-sectional feasibility study
- 30 October 2024
- Published by Elsevier in European Journal of Paediatric Neurology
- Vol. 53, 131-137
Open AccessKetogenic diet registry for epilepsy: A cross-sectional feasibility study
- Open Access
- 1 October 2024
- Published by National Institute for Health and Care Research in Efficacy and Mechanism Evaluation
- Vol. 11 (16) , 1-54
Efficacy and safety of ketogenic diet in infants with epilepsy: KIWE RCT
Background: Many infancy-onset epilepsies have a poor prognosis for seizure control and neurodevelopmental outcome. Ketogenic diets can improve seizures in older children and adults unresponsive to antiseizure medicines. We aimed to determine the effectiveness of the ketogenic diet in reducing seizure frequency compared to further antiseizure medicine in infants with drug-resistant epilepsy. Methods: In this randomised, open-label trial, 136 infants with epilepsy, aged 1–24 months, with > 4 seizures/week and a previous trial of ≥ 2 antiseizure medicines were recruited from 19 hospitals in the United Kingdom. Following a 1- or 2-week observation period, participants were randomised to receive the classical ketogenic diet or a further antiseizure medicine for 8 weeks, using a computer-generated schedule without stratification. Treatment allocation was concealed from research nurses involved in patient care, but not from participants. The primary outcome was the number of seizures/day recorded during weeks 6–8. All analyses were intention to treat. The trial is registered with the European Union Drug Regulating Authorities Clinical Trials Database (2013-002195-40). Findings: Between 1 January 2015 and 30 September 2021, 136 eligible infants were randomised. Sixty-one (78%) of 78 assigned to a ketogenic diet and 47 (81%) of 58 assigned to antiseizure medicine had primary outcome data. At 8 weeks, the number of seizures per day, accounting for the baseline rate and randomised group, was not significantly different between groups [median (interquartile range) ketogenic diet 5 (1, 16); antiseizure medicine 3 (2, 11), incidence rate ratio 1.33, 95%, confidence internal 0.84 to 2.11; p = 0.22]. A similar number of infants reported at least one serious adverse event in both groups [antiseizure medicine: 24/56 (43%), ketogenic diet: 40/78 (51%)]. The most common serious adverse events were seizures in both groups. Three infants died during the course of the trial, all of whom were randomised to the ketogenic diet arm; deaths were considered to be unrelated to treatment. Interpretation: There was no evidence that a ketogenic diet was better than further antiseizure medicine in achieving seizure control in infants with epilepsy. The two treatments were similarly tolerated and a ketogenic diet appears safe to use in infants with epilepsy. A ketogenic diet could be a treatment option in infants whose seizures continue despite trial of two standard antiseizure medicines. Study registration: This study was registered as EudraCT 2013-002195-40. Funding: This award was funded by the National Institute for Health and Care Research (NIHR) Efficacy and Mechanism Evaluation (EME) programme (NIHR award ref: 12/10/18) and is published in full in Efficacy and Mechanism Evaluation; Vol. 11, No. 16. See the NIHR Funding and Awards website for further award information.
- 1 October 2024
- Published by National Institute for Health and Care Research in Efficacy and Mechanism Evaluation
- Vol. 11 (16) , 1-54
Open AccessEfficacy and safety of ketogenic diet in infants with epilepsy: KIWE RCT
Background: Many infancy-onset epilepsies have a poor prognosis for seizure control and neurodevelopmental outcome. Ketogenic diets can improve seizures in older children and adults unresponsive to antiseizure medicines. We aimed to determine the effectiveness of the ketogenic diet in reducing seizure frequency compared to further antiseizure medicine in infants with drug-resistant epilepsy. Methods: In this randomised, open-label trial, 136 infants with epilepsy, aged 1–24 months, with > 4 seizures/week and a previous trial of ≥ 2 antiseizure medicines were recruited from 19 hospitals in the United Kingdom. Following a 1- or 2-week observation period, participants were randomised to receive the classical ketogenic diet or a further antiseizure medicine for 8 weeks, using a computer-generated schedule without stratification. Treatment allocation was concealed from research nurses involved in patient care, but not from participants. The primary outcome was the number of seizures/day recorded during weeks 6–8. All analyses were intention to treat. The trial is registered with the European Union Drug Regulating Authorities Clinical Trials Database (2013-002195-40). Findings: Between 1 January 2015 and 30 September 2021, 136 eligible infants were randomised. Sixty-one (78%) of 78 assigned to a ketogenic diet and 47 (81%) of 58 assigned to antiseizure medicine had primary outcome data. At 8 weeks, the number of seizures per day, accounting for the baseline rate and randomised group, was not significantly different between groups [median (interquartile range) ketogenic diet 5 (1, 16); antiseizure medicine 3 (2, 11), incidence rate ratio 1.33, 95%, confidence internal 0.84 to 2.11; p = 0.22]. A similar number of infants reported at least one serious adverse event in both groups [antiseizure medicine: 24/56 (43%), ketogenic diet: 40/78 (51%)]. The most common serious adverse events were seizures in both groups. Three infants died during the course of the trial, all of whom were randomised to the ketogenic diet arm; deaths were considered to be unrelated to treatment. Interpretation: There was no evidence that a ketogenic diet was better than further antiseizure medicine in achieving seizure control in infants with epilepsy. The two treatments were similarly tolerated and a ketogenic diet appears safe to use in infants with epilepsy. A ketogenic diet could be a treatment option in infants whose seizures continue despite trial of two standard antiseizure medicines. Study registration: This study was registered as EudraCT 2013-002195-40. Funding: This award was funded by the National Institute for Health and Care Research (NIHR) Efficacy and Mechanism Evaluation (EME) programme (NIHR award ref: 12/10/18) and is published in full in Efficacy and Mechanism Evaluation; Vol. 11, No. 16. See the NIHR Funding and Awards website for further award information.
- Open Access
- 7 July 2023
- Published by Elsevier in The American Journal of Human Genetics
- Vol. 110 (8) , 1356-1376
Stretch-activated ion channel TMEM63B associates with developmental and epileptic encephalopathies and progressive neurodegeneration
- 7 July 2023
- Published by Elsevier in The American Journal of Human Genetics
- Vol. 110 (8) , 1356-1376
Open AccessStretch-activated ion channel TMEM63B associates with developmental and epileptic encephalopathies and progressive neurodegeneration
- Open Access
Stretch-activated ion channel TMEM63B associates with developmental and epileptic encephalopathies and progressive neurodegeneration
By converting physical forces into electrical signals or triggering intracellular cascades, stretch-activated ion channels (SACs) allow the cell to respond to osmotic and mechanical stress. Knowledge of the pathophysiological mechanisms underlying associations of SACs with human disease is limited. Here we describe 16 unrelated patients, with severe early onset developmental and epileptic encephalopathy (DEE), intellectual disability, and severe motor and cortical visual impairment, associated with progressive neurodegenerative brain changes, carrying ten distinct de novo variants of TMEM63B , encoding for a highly conserved SAC. Variants were missense, including the recurrent V44M in 7/16 patients, or in-frame, and affected conserved residues located in transmembrane regions of the protein. In 12 patients, haematological abnormalities co-occurred, such as macrocytosis and haemolysis, requiring blood transfusions in some. We modelled V44M, R443H, and T481N in transfected Neuro2a cells and demonstrated leak inward cation currents across the mutated channel even in isotonic conditions, while the response to hypo-osmotic challenge was impaired, as were the Ca 2+ transients generated under hypo-osmotic stimulation. Ectopic expression of the V44M and G580C variants in Drosophila resulted in early death. TMEM63B -associated DEE represents a novel clinicopathological entity in which altered cation conductivity results in a severe neurological phenotype with progressive brain damage and early onset epilepsy, associated with haematological abnormalities in most patients.
Open AccessStretch-activated ion channel TMEM63B associates with developmental and epileptic encephalopathies and progressive neurodegeneration
By converting physical forces into electrical signals or triggering intracellular cascades, stretch-activated ion channels (SACs) allow the cell to respond to osmotic and mechanical stress. Knowledge of the pathophysiological mechanisms underlying associations of SACs with human disease is limited. Here we describe 16 unrelated patients, with severe early onset developmental and epileptic encephalopathy (DEE), intellectual disability, and severe motor and cortical visual impairment, associated with progressive neurodegenerative brain changes, carrying ten distinct de novo variants of TMEM63B , encoding for a highly conserved SAC. Variants were missense, including the recurrent V44M in 7/16 patients, or in-frame, and affected conserved residues located in transmembrane regions of the protein. In 12 patients, haematological abnormalities co-occurred, such as macrocytosis and haemolysis, requiring blood transfusions in some. We modelled V44M, R443H, and T481N in transfected Neuro2a cells and demonstrated leak inward cation currents across the mutated channel even in isotonic conditions, while the response to hypo-osmotic challenge was impaired, as were the Ca 2+ transients generated under hypo-osmotic stimulation. Ectopic expression of the V44M and G580C variants in Drosophila resulted in early death. TMEM63B -associated DEE represents a novel clinicopathological entity in which altered cation conductivity results in a severe neurological phenotype with progressive brain damage and early onset epilepsy, associated with haematological abnormalities in most patients.
- 10 September 2021
- Published by Elsevier
- p. 669-671
Judith “Helen” Cross